Valvular Heart Disease and Cardiomyopathy in China: Epidemiology and Current Treatments

Overview

Journal J Geriatr Cardiol

Specialty Geriatrics

Date 2024 Nov 1

PMID 39483267

Authors

Sheng-Shou Hu

Affiliations

Soon will be listed here.

Abstract

The (2022) intricate landscape of cardiovascular health in China. In connection with the previous section, this ninth section of the report offers a comprehensive analysis of valvular heart disease and cardiomyopathy. Although rheumatic valve disease is still the main cause of valvular heart disease in China, with the aging of the population and the improvement of living standards, the prevalence of degenerative valvular heart disease is on the rise. Because many patients with valvular heart disease have only mild to moderate valve stenosis or insufﬁciency, and no symptoms, the detection rate in the population is low and late, resulting in many patients been in the severe late stage of disease at visit, increasing the difﬁculty of treatment and affecting effectiveness and prognosis. Therefore, we should strengthen the examination and screening of valvular heart disease in order to ﬁnd and prevent it as early as possible. In addition, compared with other diseases, the treatment of valvular heart disease needs more and higher technical support (surgery, intervention, etc). However, not all hospitals can provide relevant technologies. At present, the treatment of valvular heart disease is still mainly concentrated in the provincial hospitals. It is necessary to carry out more professional training so that more doctors and hospitals can participate in the treatment of valvular heart disease. Cardiomyopathy is a group of myocardial diseases with abnormal myocardial structure and/or function, but couldn't be explained by hypertension, coronary atherosclerosis, valvular heart disease and congenital heart disease. It includes hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic cardiomyopathy (also known as arrhythmogenic right ventricular cardiomyopathy), restrictive cardiomyopathy (RCM) and undifferentiated cardiomyopathy.

References

He S, Deng H, Jiang J, Liu F, Liao H, Xue Y . The Evolving Epidemiology of Elderly with Degenerative Valvular Heart Disease: The Guangzhou (China) Heart Study. Biomed Res Int. 2021; 2021:9982569. PMC: 8088353. DOI: 10.1155/2021/9982569. View

Zou Y, Song L, Wang Z, Ma A, Liu T, Gu H . Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med. 2004; 116(1):14-8. DOI: 10.1016/j.amjmed.2003.05.009. View

Pang Y, Liu S, Yan L, Wang Q, Li L, Chu C . Associations of long-term exposure to traffic-related air pollution with risk of valvular heart disease based on a cross-sectional study. Ecotoxicol Environ Saf. 2020; 209:111753. DOI: 10.1016/j.ecoenv.2020.111753. View

Sun H, Hao X, Wang X, Zhou X, Zhang Y, Liu X . Genetics and Clinical Features of Noncompaction Cardiomyopathy in the Fetal Population. Front Cardiovasc Med. 2021; 7:617561. PMC: 7854697. DOI: 10.3389/fcvm.2020.617561. View

Li X, Fan X, Li S, Sun W, Shivkumar K, Zhao S . A Novel Risk Stratification Score for Sudden Cardiac Death Prediction in Middle-Aged, Nonischemic Dilated Cardiomyopathy Patients: The ESTIMATED Score. Can J Cardiol. 2020; 36(7):1121-1129. DOI: 10.1016/j.cjca.2019.11.009. View

Chen X, Li L, Cheng H, Song Y, Ji K, Chen L . Early Left Ventricular Involvement Detected by Cardiovascular Magnetic Resonance Feature Tracking in Arrhythmogenic Right Ventricular Cardiomyopathy: The Effects of Left Ventricular Late Gadolinium Enhancement and Right Ventricular Dysfunction. J Am Heart Assoc. 2019; 8(17):e012989. PMC: 6755833. DOI: 10.1161/JAHA.119.012989. View

Wang Y, Wu B, Li J, Liu H, Shu X . Distribution Patterns of Valvular and Vascular Complications in Bicuspid Aortic Valve. Int Heart J. 2020; 61(2):273-280. DOI: 10.1536/ihj.19-467. View

Chan W, Yang S, Wang J, Tong S, Lin M, Lu P . Clinical characteristics and survival of children with hypertrophic cardiomyopathy in China: A multicentre retrospective cohort study. EClinicalMedicine. 2022; 49:101466. PMC: 9157015. DOI: 10.1016/j.eclinm.2022.101466. View

Akdis D, Chen L, Saguner A, Zhang N, Gawinecka J, Saleh L . Novel plasma biomarkers predicting biventricular involvement in arrhythmogenic right ventricular cardiomyopathy. Am Heart J. 2021; 244:66-76. DOI: 10.1016/j.ahj.2021.10.187. View

10.

Wang X, Zhang X, Cao K, Zeng M, Fu X, Zheng A . Cardiac disruption of SDHAF4-mediated mitochondrial complex II assembly promotes dilated cardiomyopathy. Nat Commun. 2022; 13(1):3947. PMC: 9270418. DOI: 10.1038/s41467-022-31548-1. View

11.

Jiang S, Zhang H, Wei S, Zhang L, Gong Z, Li B . Left atrial appendage exclusion is effective in reducing postoperative stroke after mitral valve replacement. J Card Surg. 2020; 35(12):3395-3402. DOI: 10.1111/jocs.15020. View

12.

Jiao Y, Luo T, Meng X, Wang J . Decade-long mitral valve surgery trends and rheumatic heart disease: a review of mitral valve surgery in a large Chinese cardiovascular center. Ann Palliat Med. 2021; 11(4):1160-1169. DOI: 10.21037/apm-21-2005. View

13.

Yang Y, Wang Z, Chen Z, Wang X, Zhang L, Li S . Current status and etiology of valvular heart disease in China: a population-based survey. BMC Cardiovasc Disord. 2021; 21(1):339. PMC: 8276378. DOI: 10.1186/s12872-021-02154-8. View

14.

Ou-Yang W, Qureshi S, Ge J, Hu S, Li S, Yang K . Multicenter Comparison of Percutaneous and Surgical Pulmonary Valve Replacement in Large RVOT. Ann Thorac Surg. 2020; 110(3):980-987. DOI: 10.1016/j.athoracsur.2020.01.009. View

15.

Liu L, Chen S, Shi J, Qin C, Guo Y . Transcatheter Aortic Valve Replacement in Aortic Regurgitation. Ann Thorac Surg. 2020; 110(6):1959-1965. DOI: 10.1016/j.athoracsur.2020.03.112. View

16.

Chen L, Song J, Chen X, Chen K, Ren J, Zhang N . A novel genotype-based clinicopathology classification of arrhythmogenic cardiomyopathy provides novel insights into disease progression. Eur Heart J. 2019; 40(21):1690-1703. DOI: 10.1093/eurheartj/ehz172. View

17.

Liu J, Wu G, Zhang C, Ruan J, Wang D, Zhang M . Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy. Heart Rhythm. 2020; 17(10):1658-1663. DOI: 10.1016/j.hrthm.2020.04.017. View

18.

Lu F, An Z, Ma Y, Song Z, Cai C, Li B . Transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation. Heart. 2021; 107(20):1664-1670. DOI: 10.1136/heartjnl-2020-318199. View

19.

Lu S, Song K, Yao W, Xia L, Dong L, Sun Y . Simplified, minimally invasive, beating-heart technique for redo isolated tricuspid valve surgery. J Cardiothorac Surg. 2020; 15(1):146. PMC: 7301080. DOI: 10.1186/s13019-020-01192-1. View

20.

Wang W, Wang J, Yao K, Wang S, Nie M, Zhao Y . Metabolic characterization of hypertrophic cardiomyopathy in human heart. Nat Cardiovasc Res. 2024; 1(5):445-461. DOI: 10.1038/s44161-022-00057-1. View